



## Firm Overview

August 2024

# CALIGAN PARTNERS - OVERVIEW



**Caligan Partners LP manages ~ \$468MM AUM**

	CALIGAN FUND	XBI	Russell 2K
July 2024	6.56%	6.85%	10.10%
YTD	26.67%	10.94%	11.22%
Since Inception	76.81%	6.03%	11.14%

- **Fund Launched Feb 1, 2022** – concentrated portfolio of 12 - 15 smid-cap life sciences companies
- **Active Engagement** as a tool to catalyze positive change at our portfolio companies
  - The Majority of Caligan's AUM is invested in companies where we have Board Representation
  - Our goal is to improve capital allocation, strategic direction, and quality of management
- **Concentrated, Value Investing in Late-Stage Therapeutics Companies That Are Scientifically De-Risked**
  - Nearly every company in Caligan's portfolio generates revenue



**Caligan Partners LP (“Caligan”)** is an SEC-registered investment advisor focused on generating absolute returns by investing in small and midcap companies within life sciences. Caligan takes a private equity approach to public investing, performing exhaustive research, preferring longer holding periods, and partnering with operating executives with world-class expertise. Caligan invests in companies that have been largely de-risked from a regulatory standpoint (commercial products and post-Phase 3 pipelines) but have underperformed their peers for reasons that we believe are fixable within 1 - 2 years. Caligan actively engages with boards and management teams of its portfolio companies, preferring to collaborate in private but not opposed to expressing ideas in a public forum. We see a large, untapped opportunity set for shareholder engagement in life sciences given the exponential increase in the number of companies within the sector and the heightened importance of capital allocation in the current market environment.

### MANAGEMENT TEAM

- Experienced team led by **David Johnson**, former MD at The Carlyle Group and VP at Morgan Stanley
- Sr. Partners have worked at world-class firms including Carlyle, Morgan Stanley, Pershing Square, P2
- The principals have invested the majority of their liquid net worth and will reinvest at least 33% of the incentive allocation

### DIFFERENTIATED MODEL

- Team has experience as board members of public and private companies
- Focuses on large, untapped opportunity set – **shareholder activism within life sciences**
- Caligan partners with ex-CEOs and operating executives in all of their large investments



## FOUNDED UPON A CONSISTENT STRATEGY PROVEN OVER 4 YEARS ACROSS 10 CO-INVESTMENTS



Caligan Partners has demonstrated a rigorous, repeatable process highlighted by the ability to execute the following:

- **Sourcing and due diligence** of attractive investment ideas with high risk-adjusted return profiles
- **Build Positions** with a disciplined, cost-effective approach
- **Catalyze change** at portfolio companies, from inside and outside of boardrooms
- **Efficiently exit** investments within a 9 to 24-month timeframe
- **Establish credibility** across target industries by maintaining strong ethical standards, presenting data-driven conclusions for change, and integrating an operating perspective with robust financial analysis



# CALIGAN TRACK RECORD

## Fund Returns + Co-Investment Track Record

**Firm AUM: \$468MM**



### CALIGAN PARTNERS ONSHORE FUND LP

	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	YTD	XBI	Russell 2K
<b>2024</b>	1.59%	11.30%	4.60%	-4.78%	-0.78%	6.38%	6.56%						<b>26.67%</b>	<b>10.94%</b>	<b>11.22%</b>
<b>2023</b>	6.50%	-3.60%	-6.26%	0.07%	11.15%	0.87%	3.65%	3.37%	-0.11%	0.29%	-0.53%	18.47%	<b>36.57%</b>	<b>7.58%</b>	<b>15.09%</b>
<b>2022</b>	-	1.03%	10.12%	-3.02%	-2.97%	-8.97%	1.97%	5.92%	-9.39%	4.00%	-2.71%	8.32%	<b>2.21%</b>	<b>-25.87%</b>	<b>-21.56%</b>

### Co-investments (Exited)<sup>1</sup>

No.	Investment	Ticker	Sector	Market Cap (\$MM) <sup>6</sup>	Entry Date	Entry Price	Exit or Current Price	Months Held	Caligan Net MOIC <sup>2</sup>	Index TR <sup>7</sup>	Alpha
1	Knowles Corp.	KN	Tech Components	1,218	1/10/19	14.45	20.83	9	1.37x	1.31x	6%
2	AMAG Pharma	AMAG	Pharmaceuticals	304	6/21/19	8.44	13.75	17	1.53x	1.45x	8%
3	Rigel Pharmaceuticals	RIGL	Pharmaceuticals	422	10/22/20	2.60	3.79	5	1.23x	1.11x	12%
4	Jazz Pharmaceuticals <sup>3</sup>	JAZZ	Pharmaceuticals	9,465	2/26/21	164.26	167.31	1	1.04x	0.90x	14%
5	Aveo Pharmaceuticals <sup>4</sup>	AVEO	Pharmaceuticals	238	2/26/21	8.09	12.98	0.4	1.51x	0.96x	55%
6	ADMA Biologics	ADMA	Pharmaceuticals	255	7/13/21	1.28	3.24	17	2.26x	0.62x	163%
7	Standard Biotech	LAB	Life Sciences Tools	929	3/25/21	4.65	2.38	35	0.48x	0.38x	10%

### Current Co-investments as of 7/31/24<sup>1, 5</sup>

8	Liquidia Corp.	LQDA	Pharmaceuticals	1,115	4/12/21	2.81	11.86	340	3.56x	0.80x	276%
9	Alimera Sciences	ALIM	Pharmaceuticals	290	5/16/23	1.70	5.56	14	2.81x	1.16x	171%

<sup>1</sup> Past performance is not necessarily indicative of future results. Monthly returns reflect the return of the 1Y Founders Class for the Caligan Partners Onshore LP ("Fund") net of all fees (1.25% management and 17.5% performance) and Fund expenses. For purposes of calculating the performance allocation, net returns for the Founders Class assume an investment at the inception of the Fund on February 1, 2022, with no subsequent contributions or withdrawals. The returns for 2024 are unaudited and subject to change. Performance for an individual investor may vary due to a number of factors including the timing of subscriptions and redemptions, applicable fees, and new issue eligibility. The SPDR S&P Biotech ETF (XBI) and the Russell 2000 Index (^RUT) are included to allow for the comparison of the Fund's performance to that of certain well-known benchmarks since the Fund's launch on Feb 1, 2022. Comparisons to benchmarks have limitations because their composition, volatility, and other material characteristics may differ substantially from the Fund.

<sup>2</sup> MOIC calculated on a blended basis for all CV investors across multiple closings and using disclosed LPA fees, consistent with approach used for audited financials. Audited financials available upon request. Performance of separately managed accounts that invested alongside vehicle may differ due to different entry and exit timing and fees.

<sup>3</sup> MOIC is calculated as net profit divided by long market value buying power that was invested. IRR calculated as daily net cash flows from purchases and sales (including short rebates) from inception to liquidation. This investment was hedged with short \$0.40 of XBI and \$0.40 of a custom basket of shorts for every \$1 long JAZZ.

<sup>4</sup> The position was held for 15 days, causing a Net IRR of 30532438%. MOIC calculated as net profit divided by long market value buying power that was invested. IRR calculated as daily net cash flows from purchases and sales (including short rebates) from inception to liquidation. This investment was hedged with short \$0.50 of XBI for every \$1 long AVEO.

<sup>5</sup> Performance data as of July 31, 2023


<sup>6</sup> Market cap at entry

<sup>7</sup> Indices used for comparison were XBI for AMAG, RIGL, JAZZ, AVEO, LQDA, ADMA, & ALIM; ARKG for LAB. Indices are used for illustrative purposes only. One cannot invest directly in these indices. These benchmarks do not reflect the deduction of fees and expenses that are applicable to a fund vehicle.



# FUND RETURNS VS XBI - SINCE INCEPTION

## Inception To Date Compounded Returns<sup>1</sup>



<sup>1</sup> Inception of Caligan Fund is February 1, 2022

Source: Bloomberg, Caligan Calculations



# CALIGAN MASTER FUND EXHIBITS LOW CORRELATION TO BROADER INDICES



## Inception To Date Monthly Correlation of Returns <sup>1</sup>

	Caligan Fund	XBI	Russell 2000
Caligan Fund	1.00	0.53	0.52
XBI	0.53	1.00	0.73
Russell 2000	0.52	0.73	1.00

<sup>1</sup> Inception of Caligan Fund, XBI, and Russell 2000 is February 1, 2022.

Source: Bloomberg, Caligan Calculations





# MASTER FUND EXHIBITED DOWNSIDE RISK PROTECTION AND LOW BETA DURING BIOTECH DRAWDOWN



## Inception To Date Fund Statistics <sup>1</sup>

	Caligan Fund	XBI	Russell 2000
Annualized Returns	26.63%	2.45%	4.47%

Beta vs XBI	0.41
Sortino Ratio	2.09
Sharpe Ratio	1.06

<sup>1</sup> Inception of Caligan Fund, XBI, and Russell 2000 is February 1, 2022.





# ATTRIBUTES WE REQUIRE IN AN INVESTMENT

- **Products Must Have Value and Duration**

- Therapies need to fill an unmet need for patients and doctors and have few competitive threats

- **Great Management Teams Create Value**

- We can either invest in great teams, help good teams become better, or change bad teams

- **Asymmetric Return Profile**

- 3 up: 1 down and 2x MOIC within 12 -24 months

- **Competitive Positioning**

- Either be first-to-market or play in large, growing markets

- **Viable Standalone Commercial Model**

- Need to be able to support commercial infrastructure and ensure future investment


- **Strong balance sheets**
  - Cash is king; no near-term financing needs unless we are the capital solution
- **Near-term path to profitability**
  - Public companies need viable standalone strategies with competent leadership
- **Late-stage companies with catalysts**
  - Value inflecting milestones, both on-market and pipeline, in the near-term
- **Potential for horizontal consolidation**
  - Combining products to make a viable independent company; synergies serve as synthetic capital raises
- **Focused companies will outperform**

## Highly Focused Value Investors with an Activist Edge

### 1. We believe markets are generally efficient, because...

- Companies are valued based on the assumption that they will maintain the same
  - **Management team**
  - **Strategic direction**
  - **Capital allocation**

**Caligan can change these aspects of a company using the corporate governance process** in order to unlock long-term earnings power of companies



### 2. We focus on mature companies that have:

- Established proofs of concept, tangible assets, and strong intellectual property
- Underperformed their opportunity set but have problems that can be fixed
- Attractive end markets with strong secular tailwinds, (e.g., life sciences, biopharma), which provide us with conviction in the underlying outlook for revenue growth

### 3. As Activist Investors, we strive to be...

- **Active owners** who seek board seats where necessary, often in partnership with our network of operating executives, and willing to take liquidity restrictions to execute on our value-creation plans
- **Constructive**, striving to work collaboratively and privately behind the scenes to build consensus and achieve mutually beneficial outcomes
- **Willing to engage in proxy fights** if public discussion is needed

## Untapped Opportunities for Activism in Small/Midcap Life Sciences



### Target underfollowed activist opportunity set driven by complexities

Activist investors tend to avoid the inherent complexities of biopharma/life sciences companies – complexities that we have expertly managed and capitalized on for years – i.e., we find value within growth sectors.



### Driven by partnership with operators

Our Advisory Board of influential operating executives and network of scientific and industry thought leaders provide us with critical insight: domain expertise, emerging opportunities, and first-hand experience needed to test and validate our theses.



### Creating our own catalysts

We formulate our own value-creation theses that are differentiated from market expectations, and use the corporate governance process to improve management, strategy or capital allocation.



### Blending a seasoned approach with an exciting start-up opportunity

Investors have an opportunity to participate in a new, optimally structured Flagship Fund – backed by an already-established process, team, LP Base, and track record – mitigating many of the risks associated with typical start-ups and providing a strong foundation for success.




### Disciplined, all-encompassing due diligence

We stand apart from traditional funds, who are unwilling/unable to patiently conduct comprehensive due diligence. We assess the entire business ecosystem – including exhaustive interactions with competitors, suppliers, shareholders, and more – when assessing ideas.

# UNTAPPED OPPORTUNITY SET IN LIFE SCIENCES ACTIVISM

## Complexity Reduces Competition, Ensures Ample Investment Targets

*Activist investors have historically avoided biopharma & life sciences, due to the complexity and ongoing capital requirements underlying the majority of these companies...*




<sup>1</sup>S&P Capital IQ

# RECURRING THEMES ACROSS OUR INVESTMENTS

Applicable to All Target Industries and Market Environments

The following investment themes are consistent throughout the cycle and ensure our strategy remains effective in any market environment



## Concentrated, Long-Term Portfolio of Best Ideas

Portfolio Details	
Number of investments	12 – 17 Longs. Diverse short basket(s)
Single name limit	15% of NAV at cost
Top 5 long position exposure	61.5% as of July 31, 2024
13D Positions <sup>1</sup>	Exelixis, Inc. (EXEL), Liquidia Corp (LQDA), Alimera Sciences (ALIM), Anika Therapeutics (ANIK)
Current Exposures (6.30.24)	83.3% Net Long, 9.6% Cash (Short exposure typically range from 10% to 30%)
Market Cap Range	Typical investments between \$100MM and \$3BN
Key sectors	Life Sciences; Therapeutics, Devices, Tools and Diagnostics, Spec. Pharma (predominantly North America, some Western Europe)
Geographic Breakdown	86.2% North America, 13.8% Western Europe
Market Neutral SMA <sup>2</sup>	Longs Pari Passu to the Fund, with -/+ 10% Net Long Exposure

<sup>1</sup> Investments where Caligan is actively, either publicly or privately, working to effectuate changes at a portfolio company and/or has filed a Form 13D

<sup>2</sup> \$100M of additional capacity for SMA investors

# REPEATABLE, RIGOROUS INVESTMENT PROCESS

## Structured for Efficient Ideation, Diligence, and Execution

### 6. Exit

- Sell when price has reached close to intrinsic value excluding activist pressure
- Disciplined approach with regards to risk-adjusted opportunities in portfolio

### 5. Continual monitoring process

- Adapt upside/downside and price targets
- Follow industry and company fundamentals
- Evaluate the status or outcome of events

### 4. Stake Building (2+ months)

- Accumulate stakes in the most cost-effective way through a combination of cash, forwards, and options that minimizes stock movement before disclosure

### 3. Investment Decision, Engagement, Execution (6+ months)


- Identify upside/downside in active/passive scenarios
- Identify catalyst calendar and potential for accumulation/exit
- Evaluate corporate governance calendar for timing

### 1. Idea Sourcing/Screening (1-2 months)

- Internally generated ecosystem, driven by research and relationships from past investments
- Often stemming from Advisory Board, other operating partners, and shareholders
- Systematic evaluation of dislocations highlights new opportunities

### 2. Due Diligence (3+ months)

- Formalize partnerships with operating executives and other constituents
- Work jointly to develop theses and value-creation plans
- Collect insights from entire ecosystems (ex-employees, competitors, shareholders)
- Detailed modeling and scenario analysis using publicly available information
- Comprehensive review of company and sector fundamentals
- Identify structural impediments to earnings changes
- Assess multiple valuation scenarios (i.e., understand linkage between growth profile, quality, and multiple)
- Answer underlying question: What is the case for change and how will it create value?





### Quantitative risk measures

#### Manage portfolio-level risks

- Exposure levels
- Correlation to risk factors
- Market risk (beta)

#### Real-time portfolio monitoring

- Daily NAV reported
- Daily-value-at-risk analyses
- Monthly stress testing



### Qualitative risk measures

- **Concentrate idiosyncratic risks;** hedge to isolate risks we believe are mispriced
- **Portfolio allocated** to the highest risk-adjusted return ideas, sized appropriately and consistently monetized
- **Use catalyst events** to seek differentiated returns and to time investment entry and exit
- **Conduct rigorous due diligence** to build a concentrated portfolio of high-conviction investments
- **Use 'margin-of-safety' approach** when investing in growth companies
- **Use activism** as a tool to prevent losses and stagnation

# SEASONED LEADERSHIP, PROVEN ACROSS SEVERAL INVESTMENTS



## Integrating Deep Experience to Craft Our Differentiated Approach

### David Johnson Founder and Portfolio Manager

2000-2004



AB, Harvard College,  
Applied Mathematics  
SM, Harvard College,  
Applied Mathematics

2003-2004



Analyst,  
Weiss Asset Management

2004-2010



Vice President,  
Morgan Stanley

Served as a director of  
SeaChange Maritime  
Limited and observer of  
numerous boards of  
public and private  
companies

2010-2017



Managing Director,  
The Carlyle Group

Worked on corporate  
strategic initiatives  
and sat on five  
investment committees

2018



**CALIGAN**  
PARTNERS

Board of Directors  
AMAG Pharmaceuticals  
(AMAG)  
Board of Directors,  
Liquidia Corporation  
(LQDA) and Exelixis  
(EXEL)

- Board of Directors of the Children's Scholarship Fund
- Former member of the Harvard College Fund Executive Committee
- Former Chair of the Finance & Investment Committee for the Riley's Way Foundation

### Robert Laman Partner and COO

2003-2006



BA, Biology  
Boston University

2010-2011



Associate,  
FrontPoint Partners

2011-2016



Vice President  
Pershing Square  
Capital Management

2016-2018



Consultant,  
Mantle Ridge

Helped to launch  
successful activist  
SPV for CSX  
Corporation

2018



**CALIGAN**  
PARTNERS

Chief Operating Officer  
and Head of Business  
Development

# FUND TERMS AND SERVICE PROVIDERS



	Class A	Class B
Management Fee	1.50%	1.25%
Incentive Allocation	20.0% annually, subject to HWM	17.5% annually, subject to HWM
Liquidity	Quarterly, subject to 25% investor-level gate	Quarterly, subject to 12.5% investor-level gate
Initial Lock-up	One year	Two Years
Preferred Return	7%, full catch-up	7%, full catch-up
Notice period	90 days	90 days
Minimum investment	\$1 million	\$1 million
Co-investments	Fund investors will receive priority on co-investment opportunities at discounted fees (0%/10%)	
Service Providers		
Prime brokers	Morgan Stanley, Jefferies	
Legal counsel	Schulte Roth & Zabel LLP	
Fund administrator	Northern Trust	
Compliance	Silver Regulatory Associates	
Audit and tax	Ernst & Young	



## CALIGAN PARTNERS IN THE PRESS



Hyperlinks Below Contain Articles Written About Caligan's Activist Campaigns

- [JUNE 24, 2024 - ALIMERA SCIENCES \(ALIM\) IS ACQUIRED BY ANI PHARMACEUTICALS FOR \\$5.50/SHARE PLUS CVR](#)
- [JUNE 1, 2023 - FARALLON AND CALIGAN WIN PROXY CONTEST AT EXELIXIS \(EXEL\) - CALIGAN'S DAVID JOHNSON TO JOIN THE BOARD EFFECTIVE IMMEDIATELY](#)
- [MAY 17, 2023 - CALIGAN LEADS PREFERRED EQUITY PIPE INTO ALIMERA SCIENCES \(ALIM\) TO FACILITATE THE PURCHASE OF THE U.S. RIGHTS TO YUTIQ FROM EYEPOINT PHARMACEUTICALS \(EYPT\)](#)
- [APR 13, 2023 - ANIKA SETTLES WITH CALIGAN PARTNERS, REFRESHES BOARD AND AGREES TO STOCK BUYBACK PLAN](#)
- [FEBRUARY 21, 2023 - CALIGAN PARTNERS URGES ANIKA THERAPEUTICS \(ANIK\) TO CONSIDER STRATEGIC ALTERNATIVES](#)
- [FEBRUARY 4, 2022 - CALIGAN PARTNERS BUILDS A 6% ACTIVIST STAKE IN ADMA BIOLOGICS \(ADMA\)](#)
- [MAY 10, 2021 - CALIGAN PARTNERS BUILDS A 11.2% ACTIVIST STAKE IN FLUIDIGM CORP \(FLDM\)](#)
- [APRIL 13, 2021 - CALIGAN PARTNERS ANNOUNCES A 16.8% STAKE IN LIQUIDIA CORP \(LQDA\) AND DAVID JOHNSON JOINS THE BOARD OF DIRECTORS](#)
- [OCTOBER 1, 2020 - APOLLO'S COVIS PHARMA TO BUY AMAG PHARMACEUTICALS FOR \\$13.75 PER SHARE](#)
- [OCTOBER 8, 2019 - AMAG PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT WITH CALIGAN PARTNERS LP](#)
- [MAY 9, 2019 - KNOWLES CORPORATION ANNOUNCES SETTLEMENT AGREEMENT WITH CALIGAN PARTNERS LP](#)
- [MARCH 29, 2019 - CALIGAN PARTNERS LAUNCHES ACTIVIST CAMPAIGN AT KNOWLES CORPORATION](#)

## Recognizing the Untapped Break-Up Value of an Established Market Leader in Microacoustic Components

### Company Background and Opportunity

- Caligan raised \$90 million along with a partner hedge fund to pursue an activist co-investment in Knowles Corp (KN)
- Knowles was spun from its parent in 2014 and the stock materially underperformed its peers and broader equity markets
- Knowles has been the technological leader of each of its core yet unrelated business segments (microacoustic components for hearing aids, and MEMS microphones for cellphones and IoT) and has held these market leadership positions for decades

### Our Thesis

- We believed that the break-up value of the company was materially higher (+2x) than the entry trading price and that the Company was unlikely to be standalone for much longer
- Knowles traded at ~6x forward EBITDA, excluding its non-core R&D spending. Its material underperformance had been associated with poor capital allocation on two acquisitions as well as its unjustified levels of R&D spending

### The Outcome

- March 29, 2019: [Caligan announced an activist campaign](#) highlighting the capital allocation issues at the Company,
- Caligan [settled for a Board seat on May 9, 2019](#)
- The market pulled forward the earnings drag of KN's non-core R&D spending, and Caligan was able to exit within nine months

<sup>1</sup> All public materials can be found on the SEC website. Investment materials available upon request.

<sup>2</sup> MOIC and IRR calculated on a blended basis for all CV investors across multiple closings and using disclosed LPA fees, consistent with approach used for audited financials. Performance of separately managed accounts that invested alongside vehicle may differ due to different entry and exit timing and fees.

### Knowles Performance From Entry to Exit



### Key Statistics<sup>2</sup>

Weighted average entry price	\$13.84
Weighted average exit price	\$20.71
Net realized MOIC	1.43x
Net realized IRR	61%
Holding period	9 months
Sourcing	Ex-Executive
Operating Executive Partner	Yes (anonymous)

# CASE STUDY – AMAG PHARMACEUTICALS<sup>1</sup>



## Right-Sizing the Bloated Structure of an Unfocused Pharma Business

### Working Constructively Within the Board to Change Strategy

#### Company Background and Opportunity

- Small-cap Pharmaceutical company with an iron deficiency anemia drug and a portfolio of Women's Health products trading at a significant discount to comparable market multiples

#### Our Thesis

- Caligan believed AMAG's cost structure was bloated and an opportunity existed to right-size the firm and change strategic direction from within the Board
- Feraheme, one of two IV irons drugs approved for the treatment of iron deficiency anemia, is a durable asset with unappreciated growth prospects internationally. At Caligan's acquisition price, we created AMAG at <2x Feraheme revenue where their only public competitor, Vifor, trades at >7x revenue
- Ciraparantag, a novel oral anti-coagulant reversal agent, has a unique set of advantages versus the only other approved therapy, Andexxa, which was recently acquired for \$1.4Bn


#### The Outcome

- Caligan raised \$31.25m in an SPV for the co-investment
- July/August 2019: Caligan acquired a 10.3% stake
- Oct. 2019:** [Caligan settled with AMAG for 2 Board seats](#)
- April 2020: AMAG hired Scott Myers as new CEO
- Aug. 5, 2020: AMAG announced Q2-2020 results, including termination of clinical development of AMAG-423
- Oct. 1, 2020:** [AMAG announced it agreed to be acquired by Covis Pharma for \\$13.75/share \(closed Nov\)](#)

<sup>1</sup> All public materials can be found on the SEC website. Investment materials available upon request.

<sup>2</sup> MOIC and IRR calculated on a blended basis for all SPV investors across multiple closings and using disclosed LPA fees, consistent with approach used for audited financials. Performance of separately managed accounts that invested alongside vehicle may differ due to different entry and exit timing and fees.

#### AMAG Performance From Entry to Exit



#### Key Statistics<sup>2</sup>

Weighted average entry price	\$8.44
Weighted average exit price	\$13.75
Net realized MOIC	1.50x
Net realized IRR	37%
Holding period	1.5 years
Sourcing	Operating Partner Network
Operating Executive Partner	Paul Fonteyne

## Management & Board Relationships Gave Us Unique Access To PIPE Opportunity

### Company Background and Opportunity

- Liquidia Corp. (LQDA) has a novel formulation technology (PRINT) that manufactures uniform particles to allow deep lung delivery of dry powders, avoiding off-target toxicity
- Liquidia's lead clinical asset, Yutrepia, had completed a Phase III for the treatment of pulmonary hypertension and was under review by the FDA
- Roger Jeffs was on the board of LQDA


### Our Thesis

- We believe Yutrepia will become the preferred inhaled therapy for pulmonary hypertension due to its ability to titrate to higher doses than any other competitor
- Our diligence gave us high conviction that LQDA has a strong intellectual property position
- Opportunity to invest behind a strong management team led by Damian deGoa (and now Roger Jeffs)


### The Outcome

- Through Caligan's relationship with Roger, Caligan was offered the opportunity to participate in a PIPE when the Company needed incremental capital to preserve cash
- [Caligan purchased a 16% stake in the Company and David Johnson joined the board on April 13, 2021](#)
- Since Caligan joined the board, the Company has made substantial progress in executing on all facets of its plan

### Liquidia Performance From Entry to Today



### Consensus Inhaled Treprostinil TAM



## Durable assets with fully-financed business plan and near-term path to profitability

### Company Background and Opportunity

- ADMA is the only vertically-integrated manufacturer of plasma derived therapy in the US, with guidance for >\$130MM of 2022E revenue
- ADMA owns 10 plasma collection centers in various phases of development, a 600,000 liter fractionation facility, and \$130MM+ of plasma inventory, a tradeable commodity
- ADMA markets two hyperimmunoglobulins, Asceniv and NABI, which command premium pricing, and one normal source immunoglobulin, Bivigam

### Our Thesis

- ADMA traded at a discount to the value of its underlying assets due to a perpetual financing overhang since it acquired its fractionation facility
- Caligan believed there was non-dilutive capital available, in conjunction with an equity raise, that could provide the Company with all the capital it needs to get to profitability
- Given the consolidation in the plasma industry, ADMA does have scarcity value as one of the only independent producers left


### In Process

- Since disclosing our 6% stake in ADMA, it has significantly outperformed the XBI and has continued to beat and raise guidance. Caligan has reduced its exposure but remains invested within the Fund

### ADMA Performance From Entry to Today



### ADMA Quarterly Revenues (\$MM)





# CASE STUDY - EVOLUS (EOLS)



## Durable asset in growing aesthetics market with near-term path to profitability and underleveraged commercial platform

### Company Background and Opportunity

- Evolus markets **Jeuveau**, one of four approved botulinum toxins; its efficacy and safety in clinical trials were equivalent to Botox
- Since its re-launch in 1Q2021, Jeuveau has seen consistent market share growth in a toxin market that is growing low double digits annually
- Jeuveau is an aesthetic-only product; it has no approved therapeutic indications which allows Evolus to pursue innovative marketing strategies that Allergan/Abbvie cannot


### Our Thesis

- The neurotoxin market is a healthy HSD/LDD grower and has proven recession and even pandemic resistant with significant potential consumer penetration
- Jeuveau is marketed to a younger demographic, at a price point that is advantageous to both the patient and the esthetician relative to Botox
- Evolus is currently a single product company, but should reach profitability by 4Q2023


### In Process

- Since making our investment in EOLS, the company has outperformed the XBI and continued to meet or exceed guidance and demonstrate tangible progress with regards to market penetration and developing a robust customer loyalty program

### EOLS Performance From Entry to Today




### EOLS Quarterly Revenues (\$MM)



# CASE STUDY – ALIMERA SCIENCES (ALIM)



Caligan led a \$69MM PIPE into Alimera Sciences (ALIM) at \$1.70/share, as part of a holistic \$75MM deal to purchase the US Rights to Yutiq from EyePoint Pharmaceuticals (EYPT)



## Sources & Uses

### Sources

New Solar Debt	67.5
SWK Royalty	-
New ALIM Equity	69.0

### Uses

Refinance Solar Debt	48
Purchase Yutiq	75
Cash to B/S	14

**Total** **137**

**Total** **137**

## Post-Transaction Ownership

Caligan	32.5%
Velan	25.8%
New Partners	30.9%
Public	10.8%

- **Became a large shareholder of both ALIM and EYPT in early 2022**
  - In 1H 2022, Caligan became the largest shareholder of ALIM and a top 10 shareholder of EYPT, with the intention of brokering a deal that combined the commercial assets of both companies
- **Caligan was granted board seats**
  - On March 27, 2023, Caligan was granted 2 seats on the Board of Directors of ALIM in conjunction with a \$36 million private placement of Series B Preferred Stock and common stock warrants (\$1.70/share)
- **Caligan collaborated with ALIM Board and Management to affect major change in 12 months, and the end result was an acquisition of ALIM by ANI Pharmaceuticals (ANIP) for \$5.50/share plus CVRs on June 24, 2024, representing a ~3x Net MOIC**
  - Caligan aligned ALIM management with an appropriate incentive structure, negotiated deal terms, and recruited other like-minded shareholders to round out the capital needed to fund the purchase of YUTIQ. Caligan refreshed the C-suite and drove cost synergies that attracted unsolicited strategic interest

## David Johnson

Founder and Chief Investment Officer



## Advisory Board

### Robert Laman

Partner and COO



### Tiffany Crowley

CFO and CCO



### Director of Research (MD/MBA)

Summer 2024 Hire



### Charlie Lee, MD/MBA Candidate

Consultant



### Dr. Roger Jeffs

CEO of Liquidia Corp. and Former CEO of  
United Therapeutics (UTHR)



### Paul Fonteyne

Former CEO of Boehringer Ingelheim  
and Director at AMAG Pharma



### Dr. Frank Witney

Former CEO of Affymetrix, Dionex, and  
Packard Biosciences



### Scott Myers

CEO of Viridian, Former CEO of AMAG  
Pharma, Cascadian, Aerocrine



**David Johnson** is the Founder and Managing Partner of Caligan Partners LP, an SEC-registered investment firm founded in 2018. He manages the growth and strategic direction of the Firm and is responsible for the Fund's investments. Mr. Johnson has a controlling interest in Caligan Partners GP and the Firm.

Previously, Mr. Johnson was a Managing Director at The Carlyle Group, where he was employed from 2010 - 2017. At Carlyle, Mr. Johnson was involved in many of the firm's strategic initiatives and sat on investment committees for a number of different funds that invested in both equity and credit. Prior to joining Carlyle, Mr. Johnson worked for 6 years at Morgan Stanley, where he was a Vice President in the Principal Investments area. In this role, Mr. Johnson served as a director and an observer to numerous boards of public and private companies.

Mr. Johnson currently serves on the board of directors for Liquidia Corp. (LQDA), a biopharmaceutical company that specializes in the treatment of Pulmonary Hypertension. Mr. Johnson also joined the board of Exelixis (EXEL) on June 1, 2023 as a result of a successful proxy contest. Mr. Johnson has also recently served on the board of AMAG Pharmaceuticals from 2019 - 2020 where he joined following the settlement of an activist campaign, oversaw the replacement of the management team followed by a sale of the company. He has formerly served on the Executive Committee for the Harvard College Fund, has served as Chair of the Finance & Investment Committee for the Riley's Way Foundation, and is a member of the board of directors of the Children's Scholarship Fund.

Mr. Johnson received his A.B. in Applied Mathematics, cum laude, from Harvard College in 2004 and a S.M. in Applied Mathematics from Harvard College in 2004.

## **Robert Laman**

Mr. Laman joined Caligan Partners in April 2018 as Partner and COO. Before joining Caligan, Mr. Laman was a Consultant for Mantle Ridge LP, a large-cap activist investment firm led by Paul Hilal. Prior to Mantle Ridge, Mr. Laman was a V.P. at Pershing Square Capital Management, an activist fund led by Bill Ackman, where he served for 6 years on their Marketing and Investor Relations Team.

Mr. Laman received a B.A. in Biology from Boston University in 2006.

## **Tiffany Crowley**

Ms. Crowley joined Caligan Partners as Partner, CFO, and CCO in November 2021. Before joining Caligan Partners, Ms. Crowley served as the CFO and CCO of Center Lake Capital Management LLC, a technology focused long/short equity investment firm. Prior to Center Lake, Ms. Crowley was a Controller at P2 Capital Partners LLC, a strategic equity investment firm, where she was responsible for fund accounting, operations, and compliance of the firm. Prior to that, Ms. Crowley was an Assurance Senior at Ernst & Young focusing on financial statement audits of hedge funds. She began her career at Berdon LLP, a mid-size public accounting firm.

Ms. Crowley received a B.B.A. in Accounting from Baruch College in 2010 and is a Certified Public Accountant in New York.



# DISCLAIMER



THE INFORMATION CONTAINED IN THIS PRESENTATION (THE "PRESENTATION") REGARDING CALIGAN PARTNERS MASTER FUND, LP (THE "FUND") IS PROVIDED BY CALIGAN PARTNERS LP ("CALIGAN") FOR INFORMATIONAL AND DISCUSSION PURPOSES ONLY, IS SUBJECT TO CHANGE AND WILL BE SUBJECT IN ITS ENTIRETY TO THE TERMS AND CONDITIONS SET FORTH IN THE FUND'S OFFERING DOCUMENTS (THE "OFFERING DOCUMENTS"). THIS PRESENTATION IS NOT, AND MAY NOT BE RELIED ON IN ANY MANNER AS, LEGAL, TAX OR INVESTMENT ADVICE OR AS AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY AN INTEREST IN THE FUND. A PRIVATE OFFERING OF INTERESTS IN THE FUND (THE "INTERESTS") WILL ONLY BE MADE PURSUANT TO THE OFFERING DOCUMENTS, WHICH WILL BE FURNISHED TO QUALIFIED INVESTORS ON A CONFIDENTIAL BASIS AT THEIR REQUEST FOR THEIR CONSIDERATION IN CONNECTION WITH SUCH OFFERING. NO PERSON HAS BEEN AUTHORIZED TO MAKE ANY STATEMENT CONCERNING THE FUND OTHER THAN AS SET FORTH IN THE OFFERING DOCUMENTS AND ANY SUCH STATEMENTS, IF MADE, MAY NOT BE RELIED UPON.

THE INTERESTS HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, THE SECURITIES LAWS OF ANY OTHER STATE OR THE SECURITIES LAWS OF ANY OTHER JURISDICTION, NOR IS SUCH REGISTRATION CONTEMPLATED. THE INTERESTS HAVE NOT BEEN AND WILL NOT BE APPROVED OR DISAPPROVED BY THE U.S. SECURITIES AND EXCHANGE COMMISSION OR BY THE SECURITIES REGULATORY AUTHORITY OF ANY STATE OR OF ANY OTHER JURISDICTION. THE FUND WILL NOT BE REGISTERED AS AN INVESTMENT COMPANY UNDER THE INVESTMENT COMPANY ACT OF 1940, AS AMENDED (THE "INVESTMENT COMPANY ACT"). CONSEQUENTLY, INVESTORS IN THE FUND ARE NOT AFFORDED THE PROTECTIONS OF THE INVESTMENT COMPANY ACT.

THE INFORMATION CONTAINED HEREIN MUST BE KEPT STRICTLY CONFIDENTIAL AND MAY NOT BE REPRODUCED OR REDISTRIBUTED TO ANY PERSON IN ANY FORMAT WITHOUT THE APPROVAL OF CALIGAN.

AN INVESTMENT IN THE FUND INVOLVES SIGNIFICANT RISKS, INCLUDING LOSS OF THE ENTIRE INVESTMENT. PRIVATE FUNDS, SUCH AS THE FUND, ARE SPECULATIVE INVESTMENTS AND ARE NOT SUITABLE FOR ALL INVESTORS, NOR DO THEY REPRESENT A COMPLETE INVESTMENT PROGRAM. PRIVATE FUNDS ARE AVAILABLE ONLY TO QUALIFIED INVESTORS WHO ARE COMFORTABLE WITH THE SUBSTANTIAL RISKS ASSOCIATED WITH INVESTING IN PRIVATE FUNDS.

THE INTERESTS IN THE FUND ARE ILLIQUID, AS THERE IS NO SECONDARY MARKET FOR INTERESTS IN THE FUND AND NONE IS EXPECTED TO DEVELOP. THERE ARE RESTRICTIONS ON TRANSFERRING INTERESTS IN THE FUND, INVESTMENTS MAY BE LEVERAGED AND THE INVESTMENT PERFORMANCE MAY BE VOLATILE. BEFORE DECIDING TO INVEST IN THE FUND, PROSPECTIVE INVESTORS SHOULD READ THE OFFERING DOCUMENTS AND PAY PARTICULAR ATTENTION TO THE RISK FACTORS CONTAINED IN THE FUND'S CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM. THE FEES AND EXPENSES CHARGED IN CONNECTION WITH AN INVESTMENT IN THE FUND MAY BE HIGHER THAN THE FEES AND EXPENSES OF OTHER INVESTMENT ALTERNATIVES AND MAY OFFSET PROFITS. INVESTORS SHOULD HAVE THE FINANCIAL ABILITY AND WILLINGNESS TO ACCEPT THE RISK CHARACTERISTICS OF THE FUND'S INVESTMENTS.

IN CONSIDERING ANY PERFORMANCE DATA CONTAINED HEREIN, PROSPECTIVE INVESTORS SHOULD BEAR IN MIND THAT PAST OR TARGETED PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS, AND THERE CAN BE NO ASSURANCE THAT THE FUND WILL ACHIEVE COMPARABLE RESULTS OR THAT TARGET RETURNS WILL BE MET. PROSPECTIVE INVESTORS SHOULD ALSO BEAR IN MIND THAT PAST OR TARGETED PORTFOLIO CHARACTERISTICS ARE NOT INDICATIVE OF FUTURE PORTFOLIO CHARACTERISTICS AND THERE CAN BE NO ASSURANCE THAT THE FUND WILL HAVE COMPARABLE PORTFOLIO CHARACTERISTICS OR THAT TARGET PORTFOLIO CHARACTERISTICS WILL BE ACHIEVED. THE IRRS PRESENTED ON A "GROSS" BASIS DO NOT REFLECT ANY MANAGEMENT FEES, CARRIED INTEREST, TAXES AND ALLOCABLE EXPENSES BORNE BY INVESTORS, WHICH IN THE AGGREGATE MAY BE SUBSTANTIAL. ALL IRRS PRESENTED ARE ANNUALIZED AND CALCULATED ON THE BASIS OF MONTHLY INVESTMENT INFLOWS AND OUTFLOWS. NOTHING CONTAINED HEREIN SHOULD BE DEEMED TO BE A PREDICTION OR PROJECTION OF FUTURE PERFORMANCE OF THE FUND.

PROSPECTIVE INVESTORS SHOULD MAKE THEIR OWN INVESTIGATIONS AND EVALUATIONS OF THE INFORMATION CONTAINED HEREIN. EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN ATTORNEY, BUSINESS ADVISER AND TAX ADVISER AS TO LEGAL, BUSINESS, TAX AND RELATED MATTERS CONCERNING THE INFORMATION CONTAINED HEREIN AND THE INTERESTS.

EXCEPT WHERE OTHERWISE INDICATED HEREIN, THE INFORMATION CONTAINED HEREIN, INCLUDING STATEMENTS CONCERNING FINANCIAL MARKET TRENDS, IS BASED ON MATTERS AS THEY EXIST AS OF THE DATE OF PREPARATION AND NOT AS OF ANY FUTURE DATE, AND WILL NOT BE UPDATED OR OTHERWISE REVISED TO REFLECT INFORMATION THAT SUBSEQUENTLY BECOMES AVAILABLE, OR CIRCUMSTANCES EXISTING OR CHANGES OCCURRING AFTER THE DATE HEREOF.

CERTAIN INFORMATION CONTAINED HEREIN CONSTITUTES "FORWARD-LOOKING STATEMENTS," WHICH CAN BE IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY SUCH AS "MAY," "WILL," "SHOULD," "EXPECT," "ANTICIPATE," "TARGET," "PROJECT," "ESTIMATE," "INTEND," "CONTINUE" OR "BELIEVE," OR THE NEGATIVES THEREOF OR OTHER VARIATIONS THEREON OR COMPARABLE TERMINOLOGY. DUE TO VARIOUS RISKS AND UNCERTAINTIES, ACTUAL EVENTS OR RESULTS OR THE ACTUAL PERFORMANCE OF THE FUND MAY DIFFER MATERIALLY FROM THOSE REFLECTED OR CONTEMPLATED IN SUCH FORWARD-LOOKING STATEMENTS. PROSPECTIVE INVESTORS IN THE FUND SHOULD NOT RELY ON THESE FORWARD-LOOKING STATEMENTS IN DECIDING WHETHER TO INVEST IN THE FUND.

CERTAIN INFORMATION CONTAINED HEREIN HAS BEEN OBTAINED FROM SOURCES OUTSIDE OF CALIGAN. WHILE SUCH INFORMATION IS BELIEVED TO BE RELIABLE FOR THE PURPOSES USED HEREIN, NEITHER CALIGAN NOR OR ANY OF ITS RESPECTIVE AFFILIATES OR PARTNERS, MEMBERS OR EMPLOYEES, ASSUME ANY RESPONSIBILITY FOR THE ACCURACY OF SUCH INFORMATION.



## Contact

---

### **CALIGAN PARTNERS LP**

515 Madison Ave, 8th Floor  
New York, NY 10022

Tel. +1.646.859.8205

Email. [ir@caliganpartners.com](mailto:ir@caliganpartners.com)